Global Alzheimer's Drugs Market 2014-2018 - New Market Research Report

From: Fast Market Research, Inc.
Published: Fri Jul 11 2014


Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.

Full Report Details at
- http://www.fastmr.com/prod/842593_global_alzheimers_drugs_market_20142018.aspx?afid=301

TechNavio's analysts forecast the Global Alzheimer's Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Alzheimer's Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer's disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer's Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Alzheimer's Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer's Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

* Americas
* EMEA
* APAC

Key Vendors

* Eisai Co., Ltd.
* Forest Laboratories Inc.
* Janssen Pharmaceuticals Inc.
* Novartis AG

Other Prominent Vendors

* Adamas Pharmaceuticals Inc.
* Archer Pharmaceuticals Inc.
* Eli Lilly and Co.
* F. Hoffmann-La Roche Ltd.
* FORUM Pharmaceuticals Inc.
* H. Lundbeck A/S
* Merck & Co., Inc.
* MorphoSys AG

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Global Generic Drugs Market 2014-2018
- Global Pain Management Drugs Market 2014-2018
- Global CRAMS Market Outlook to 2018 - India and China Present Bright Prospects
- Global Dermatological Drugs Market 2014-2018
- Biosimilars Market - Global Forecast to 2018
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »